A new study has found an association between good type 1 diabetes management and the use of GLP-1RA receptor agonists and SGLT2 inhibitors in real-world practice.
During the experiment, a team of researchers examined the health outcomes of 104 adults living with type 1 diabetes who either used GLP-1RA receptor agonists (GLP-1RAs) or SGLT2 inhibitors (SGLT2is).
After one year of therapy, they found that GLP-1RA users had significant reductions in weight, HbA1c and total daily dose of insulin.
SGLT2i users also had statistically significant reductions in HbA1c and basal insulin, the study has reported.
The results state: “GLP-1RA users compared to SGLT2i users had greater reduction in weight (P = .027) while HbA1c reduction was comparable between the groups.
“Over a mean total duration of use of 29.5 months/patient for both groups, more SGLT2i users experienced diabetic ketoacidosis (DKA) (12.8 per cent vs 3.9 per cent).”
They added: “Therapy was discontinued because of adverse events 26.9 per cent of the time for GLP-1RA users vs 27.7 per cent for SGLT2i users.
“GLP-1RA and SGLT2i use in type 1 diabetes is associated with clinically relevant benefits. DKA remains a clinical concern with SGLT2i use, requiring careful selection and monitoring, with the risk to benefit ratio of treatment evaluated at an individual level.”
To read the study, click here.
Register an account or login to comment
Diabetes UK issues latest guidance on coronavirus
People with diabetes urged to be ‘particularly stringent’ amid COVID-19 pandemic
NHS Drug Tariff approval for FreeStyle Libre System
Updated metformin and B12 guidance published
Criticism over Eatwell Plate amid calls for low carb approach
Type 1 man no longer requires insulin
Man commended for living with diabetes for 80 years
Warning over Lucozade sugar reduction
FreeStyle® Libre 2 includes optional real-time alarms
Novo Nordisk UK launches Ozempic® (semaglutide)
Afon Technology receives multi million cash injection to help transform the lives of people with diabetes
New ADA guidance issued
Diabetes UK publishes top research priorities to prevent health inequalities
Nurse attributes her diabetes career to CDEP
Entries open for Named Lectures Awards 2024
Quarter of adults in England are obese, new data shows
Type 2 diabetes remission not triggered by regular care processes, research reveals
Let people with diabetes choose their own medication, researchers say
Diabetes footcare to take centre stage at national conference
Diabetes consultant appointed new ABCD Chair
Highly Specialised Diabetes Nurse
Consultant in Diabetes & Endocrinology
Specialist Midwife for Diabetes
Diabetes Lead Dietitian – Young Adults
Paediatric Diabetes Specialist Nurse
Diabetes Nurse Specialist
Specialist Paediatric Diabetes Dietitian
Diabetes Research Nurse
Diabetes Inpatient Specialist Nurse
Diabetes Specialist Nurse
The Diabetes Times © 2022
GLP-1RA receptor agonists and SGLT2 inhibitors beneficial for … – DiabetesTimes.co.uk
Byadmin
Dec 23, 2022